Table 1.
LGL/MDS patient series
| UPN number | Diagnosis | Age years | Cytogenetics | LGL Count K/µL | STAT3 mutation | TCR VB | Clone size % | Flow cytometry | TCR rearrangement | Treatment (Response) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. | AML | 72 | 44,XY,del(7)(q22),−16, −17,−18,−20,+2mar[2]/45,idem,+8[10]/46,XY[8] | 634 | – | Vβ5.3 | 27 | + | + | CsA |
| 2. | RCMD | 82 | 45,XY,−7[10]/46,XY,del(5)(q13q33)[1]/46,XY[9] | 1776 | – | Vβ22 Vβ11 | 129 | + | − | Observation for LGL, darbepoetin, azacitidine |
| 3. | RA | 66 | 45,X,−X[20] | 129a | – | Vβ1 | 50 | + | + | CsA |
| 4. | RAEB-1 | 63 | 46, XY[20] | 990 | – | Vβ3 Vβ16 |
15 15 |
− | + | Observation for LGL, decitabine for MDS |
| 5. | RCMD | 71 | 46,XX[20] | 537 | – | Vβ2 | 51 | + | − | CsA+prednisone, darbepoetin, azacitidine |
| 6 | RCMD | 76 | 46,XY,del(20)(q11.2q13.1)[8]/46,XY[12] | 1120 | – | Vβ14 Vβ2 |
61 15 |
+ | + | CTx |
| 7. | CMML | 78 | 46, XX[20] | 680 | – | Vβ14 | 25 | + | + | CsA, tacrolimus, alemtuzumab |
| 8. | sAML | 62 | 46, XY[20] | 350a | – | Vβ2 | 18.1 | − | + | MTx |
| 9. | sAML | 69 | 46,XY,−7,+mar[2]/46,XY[19] | 2735 | p.D661V | N/A | N/A | + | + | CsA, Etanercept, Lenalidomide |
| 10. | RAEB-1 | 84 | 46,XX[20] | 6188 | p.D661V | Vβ21.3 | 88 | + | + | CsA, Tacrolimus, Tofacitinib, MTx +prednisone(NO) |
| 11. | ICUS | 72 | 47,XY,+mar?c[13]/46,XY[7] | 1600 | – | Vβ3 | 65 | + | + | CsA, MTx, Danazol, darbepoetin, low dose decitabine, lenalidomide(NO) |
| 12. | RA | 79 | 47,XY,+8[16]/46,XY[4] | 2100 | – | N/A | 87 | + | + | Epopoietin alfa, |
| 13. | t-AML | 36 | 48,XX,+1,der(1;7)(q10; p10),+8,+21[14]/46,XX[6] | 5780 | – | Vβ13.2 | 17 | + | + | CsA, MTx, tofacitinib, eltrombopag, pegfilgrastim, IVIG |
Detailed description of patients with MDS/LGL including cytogenetics, WHO staging and diagnostic criteria
a
Patient with LGL counts available from blood samples obtained post initiation of treatment and therefore explaining the low LGL counts